Key facts
- One Biosciences (Biotechnology)’s last known valuation is $35.8M (Jul 2025).
- It has raised $22.9M; the latest was Later Stage VC ($17.3M) in Jul 2025.
- Notable investors include Kima Ventures, Agoranov, Sofinnova Partners, The Invus Group, Galion.exe — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for One Biosciences (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for One Biosciences (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About One Biosciences (Biotechnology)
Developer of AI-powered single-cell diagnostic technology designed to integrate functional tumor profiling into clinical practice. The company's platform extracts high-quality single-cell data from FFPE and frozen biopsy samples, generates automated functional reports with rapid turnaround time and delivers detailed insights using proprietary profiles for therapy selection and development, enabling oncologists, researchers and clinical trial designers to get enhanced precision, improved treatment planning and faster decision-making.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2020
- Website
- onebiosciences.fr/
- Ownership
- Privately Held (backing)
One Biosciences (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in One Biosciences (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on One Biosciences (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.